dociparstat sodium

Dociparstat sodium is a chemically modified heparin derivative in which the 2-O and 3-O sulfate groups are removed, resulting in a compound with minimal anticoagulant activity but retaining anti-inflammatory, immunomodulatory, and antineoplastic properties. It acts through multiple mechanisms including inhibition of the CXCL12/CXCR4 axis, blocking high mobility group box 1 protein (HMGB1), inhibiting P-selectin and platelet factor 4 interactions, as well as human leukocyte elastase. Dociparstat sodium was developed primarily for hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), aiming to disrupt leukemic stem cell retention in bone marrow niches and enhance chemosensitivity. The drug has orphan designation for AML but development has been discontinued for several indications[1][2][3][4][6].

Other names

2,3-o-desulfated heparin (12000 da)2-O, 3-O desulfated heparin sodium (12000 DA)